Idiopathic pulmonary fibrosis therapeutics coming of age: ATS 2016
Marilyn Glassberg recently travelled to San Francisco to attend the American Thoracic Society’s (ATS) 2016 International Conference (13–18 May 2016)… Read more »
Dr Glassberg is a pulmonologist specializing in interstitial and rare lung diseases. She has conducted NIH-funded, industry-sponsored, and investigator-initiated clinical trials in patients with idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and lymphangioleiomyomatosis. She has completed the first clinical trial on the safety of intravenous infusion of bone-marrow derived mesenchymal stem cells (MSCs) in patients with IPF endorsed by the US Food and Drug Administration (FDA) and reported safety.
Latest posts by Marilyn K Csete Glassberg (see all)